Stereotactic Body Radiotherapy or Standard of Care for Prostate Oligoprogressive Cancer

This study is testing whether targeted radiation (stereotactic body radiotherapy, SBRT) to a small number of progressing tumour sites — a strategy called oligoprogression treatment — can help men with castration-resistant metastatic prostate cancer (cancer that keeps growing despite hormone therapy) stay on their current systemic treatment longer. **You may be eligible if...** - You are over 18 with confirmed prostate adenocarcinoma - Your cancer has progressed despite hormone-blocking treatment (castration-resistant prostate cancer) - You have fewer than 10 sites showing progression on imaging - All progressing spots can safely receive targeted radiation - You have been receiving systemic treatment for more than 3 months - Your general health is adequate (ECOG 0–3) **You may NOT be eligible if...** - You have spinal cord compression - You have any contraindication to receiving radiation therapy Talk to your doctor to see if this trial is right for you.